---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-315472"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2021-11-01T23:59:59+00:00"
generated_at: "2026-06-28T15:40:31.651376+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aadi appoints Scott Giacobello as CFO, replacing interim CFO Lance Thibault

## Summary
- Scott Giacobello appointed CFO and Treasurer, effective Nov 28, 2021; part-time from Nov 1.
- Compensation: $450k base salary, bonus up to 45% of base, and option for 200k shares vesting over 4 years.
- Giacobello was CFO of GW Pharma (acquired by Jazz for $7.2B); led EPIDIOLEX launch with $296M first-year sales.
- Company faces PDUFA date Nov 26, 2021 for lead drug FYARRO in malignant PEComa.
- Lance Thibault, interim CFO since July 2021, will leave the role on the effective date.

## SEC filing metadata
- accession: 0001193125-21-315472
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2021-11-01T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312521315472/0001193125-21-315472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312521315472/d173598d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-315472
- JSON: https://secwatch.observer/filing/0001193125-21-315472.json
- Plain text: https://secwatch.observer/filing/0001193125-21-315472.txt

## Key facts
- Executive change
  Scott Giacobello was appointed as Chief Financial Officer and Treasurer at Whitehawk Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Treasurer
  source text: appointed Scott Giacobello as its Chief Financial Officer and Treasurer, effective November 28, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521315472/0001193125-21-315472-index.htm
- Executive change
  Lance Thibault departed as interim Chief Financial Officer at Whitehawk Therapeutics, Inc..
  - Action: cease to be the interim Chief Financial Officer
  - Role: interim Chief Financial Officer
  source text: Lance Thibault, who has served as the interim Chief Financial Officer since July 2021, will cease to be the interim Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521315472/0001193125-21-315472-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.